Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015

被引：251

作者：

Gillessen, S. ^{[1
]}

Omlin, A. ^{[1
]}

Attard, G. ^{[2
,3
,4
]}

de Bono, J. S. ^{[2
,3
,4
]}

Efstathiou, E. ^{[5
,6
,7
]}

Fizazi, K. ^{[8
]}

Halabi, S. ^{[9
]}

Nelson, P. S. ^{[10
]}

Sartor, O. ^{[11
]}

Smith, M. R. ^{[12
]}

Soule, H. R. ^{[13
]}

Akaza, H. ^{[14
]}

Beer, T. M. ^{[15
]}

Beltran, H. ^{[16
]}

Chinnaiyan, A. M. ^{[17
,18
,19
]}

Daugaard, G. ^{[20
]}

Davis, I. D. ^{[21
]}

De Santis, M. ^{[22
,23
]}

Drake, C. G. ^{[24
,25
]}

Eeles, R. A. ^{[26
,27
]}

Fanti, S. ^{[28
]}

Gleave, M. E. ^{[29
]}

Heidenreich, A. ^{[30
]}

Hussain, M. ^{[31
]}

James, N. D. ^{[32
]}

Lecouvet, F. E. ^{[33
,34
]}

Logothetis, C. J. ^{[5
,6
]}

Mastris, K. ^{[35
]}

Nilsson, S. ^{[36
]}

Oh, W. K. ^{[37
]}

Olmos, D. ^{[38
,39
,40
]}

Padhani, A. R. ^{[41
]}

Parker, C. ^{[42
,43
,44
]}

Rubin, M. A. ^{[45
]}

Schalken, J. A. ^{[46
]}

Scher, H. I. ^{[16
,47
]}

Sella, A. ^{[48
]}

Shore, N. D. ^{[49
]}

Small, E. J. ^{[50
]}

Sternberg, C. N. ^{[51
]}

Suzuki, H. ^{[52
]}

Sweeney, C. J. ^{[53
,54
]}

Tannock, I. F. ^{[55
]}

Tombal, B. ^{[56
]}

机构：

[1] Kantonsspital St Gallen, Dept Oncol Haematol, St Gallen, Switzerland

[2] Royal Marsden NHS Fdn Trust, Prostate Canc Targeted Therapy Grp, Sutton, Surrey, England

[3] Royal Marsden NHS Fdn Trust, Drug Dev Unit, Sutton, Surrey, England

[4] Inst Canc Res, Sutton, Surrey, England

[5] Univ Texas Houston, MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA

[6] Univ Texas MD Anderson Canc Ctr, David H Koch Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA

[7] Natl & Kapodistrian Univ Athens, Alexandra Hosp, Dept Clin Therapeut, Sch Med, Athens 11528, Greece

[8] Univ Paris 11, Inst Gustave Roussy, Dept Canc Med, Villejuif, France

[9] Duke Univ, Dept Biostat & Bioinformat, Durham, NC 27706 USA

[10] Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98104 USA

[11] Tulane Univ, Tulane Canc Ctr, New Orleans, LA 70118 USA

[12] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[13] Prostate Canc Fdn, Santa Monica, CA USA

[14] Univ Tokyo, Adv Sci & Technol Res Ctr, Tokyo, Japan

[15] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA

[16] Weill Cornell Med Coll, Dept Med, New York, NY USA

[17] Univ Michigan, Sch Med, Dept Pathol, Michigan Ctr Translat Pathol, Ann Arbor, MI USA

[18] Univ Michigan, Sch Med, Ctr Comprehens Canc, Dept Urol, Ann Arbor, MI USA

[19] Univ Michigan, Sch Med, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA

[20] Copenhagen Univ Hosp, Rigshosp, Dept Oncol, Copenhagen, Denmark

[21] Monash Univ & Eastern Hlth, Eastern Hlth Clin Sch, Box Hill, Vic, Australia

[22] Univ Warwick, Canc Res Ctr, Warwick, England

[23] Kaiser Franz Josef Spital, Ludwig Boltzmann Inst Appl Canc Res, Vienna, Austria

[24] Johns Hopkins Univ, Sch Med, Johns Hopkins Sidney Kimmel Canc Ctr, Baltimore, MD USA

[25] Johns Hopkins Univ, Sch Med, Brady Urol Inst, Dept Urol, Baltimore, MD USA

[26] Inst Canc Res, London SW3 6JB, England

[27] Royal Marsden NHS Fdn Trust, London, England

[28] Univ Bologna, Policlin S Orsola, Dept Nucl Med, Bologna, Italy

[29] Univ British Columbia, Vancouver Prostate Ctr, Urol Sci, Vancouver, BC V5Z 1M9, Canada

[30] Rhein Westfal TH Aachen, Klinik & Poliklin Urol, Aachen, Germany

[31] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA

[32] Univ Hosp Birmingham, Queen Elizabeth Hosp Birmingham, Birmingham, W Midlands, England

[33] Clin Univ St Luc, Ctr Canc, Dept Radiol, B-1200 Brussels, Belgium

[34] Clin Univ St Luc, Inst Rech Expt & Clin, B-1200 Brussels, Belgium

[35] Europa Uomo Prostate Patients, Clayhall Ilford, Essex, England

[36] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden

[37] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Div Haematol & Med Oncol, New York, NY 10029 USA

[38] Spanish Natl Canc Res Ctr CNIO, Prostate Canc Clin Res Unit, Madrid, Spain

[39] Hosp Univ Virgen Victoria & Reg Malaga, CNIO IBIMA Genitourinary Canc Unit, Malaga, Spain

[40] Ctr Integral Onco Clara Campal CIOCC, Madrid, Spain

[41] Mt Vernon Canc Ctr, Paul Strickland Scanner Ctr, Northwood, Middx, England

[42] Royal Marsden NHS Fdn Trust, Acad Urol Unit, Prostate Canc Targeted Therapy Grp, Sutton, Surrey, England

[43] Royal Marsden NHS Fdn Trust, Dept Diagnost Radiol, Sutton, Surrey, England

[44] Inst Canc Res, Sutton, Surrey, England

[45] Weill Cornell Med Coll & NewYork Presbyterian, Dept Pathol & Urol, Meyer Canc Ctr, Inst Precis Med, New York, NY USA

[46] Radboud Univ Nijmegen, Med Ctr, Dept Urol, NL-6525 ED Nijmegen, Netherlands

[47] Mem Sloan Kettering Canc Ctr, Dept Med, Genitourinary Oncol Serv, New York, NY 10021 USA

[48] Tel Aviv Univ, Sackler Sch Med, Assaf Harofeh Med Ctr, Dept Oncol, Zerifin, Israel

[49] Carolina Urol Res Ctr, Dept Urol, Myrtle Beach, SC USA

[50] UCSF, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

来源：

ANNALS OF ONCOLOGY | 2015年 / 26卷 / 08期

关键词：

advanced prostate cancer; castration-resistant prostate cancer; therapeutics; consensus; castration-naive prostate cancer; METASTASIS-FREE SURVIVAL; INTERMITTENT ANDROGEN SUPPRESSION; SPINAL-CORD COMPRESSION; III EXTENSION TRIAL; ABIRATERONE ACETATE; PHASE-III; BONE METASTASES; ZOLEDRONIC ACID; OPEN-LABEL; ANTITUMOR-ACTIVITY;

D O I：

10.1093/annonc/mdv257

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

The first St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) Expert Panel identified and reviewed the available evidence for the ten most important areas of controversy in advanced prostate cancer (APC) management. The successful registration of several drugs for castration-resistant prostate cancer and the recent studies of chemo-hormonal therapy in men with castration-naive prostate cancer have led to considerable uncertainty as to the best treatment choices, sequence of treatment options and appropriate patient selection. Management recommendations based on expert opinion, and not based on a critical review of the available evidence, are presented. The various recommendations carried differing degrees of support, as reflected in the wording of the article text and in the detailed voting results recorded in supplementary Material, available at Annals of Oncology online. Detailed decisions on treatment as always will involve consideration of disease extent and location, prior treatments, host factors, patient preferences as well as logistical and economic constraints. Inclusion of men with APC in clinical trials should be encouraged.

引用

页码：1589 / 1604

页数：16

共 91 条

[1]

The Effect of Prior Androgen Synthesis Inhibition on Outcomes of Subsequent Therapy With Docetaxel in Patients With Metastatic Castrate-Resistant Prostate Cancer [J].

Aggarwal, Rahul ;

Halabi, Susan ;

Kelly, William Kevin ;

George, Daniel ;

Mahoney, John F. ;

Millard, Frederick ;

Stadler, Walter M. ;

Morris, Michael J. ;

Kantoff, Philip ;

Monk, J. Paul ;

Carducci, Michael ;

Small, Eric J. .

CANCER, 2013, 119 (20) :3636-3643

[2]

AKAKURA K, 1993, CANCER, V71, P2782, DOI 10.1002/1097-0142(19930501)71:9<2782::AID-CNCR2820710916>3.0.CO

[3]

2-Z

[4]

Akaza H, 2014, ANN ONCOL S4, V25, piv255

[5]

Combined Androgen Blockade With Bicalutamide for Advanced Prostate Cancer Long-Term Follow-Up of a Phase 3, Double-Blind, Randomized Study for Survival [J].

Akaza, Hideyuki ;

Hinotsu, Shiro ;

Usami, Michiyuki ;

Arai, Yoichi ;

Kanetake, Hiroshi ;

Naito, Seiji ;

Hirao, Yoshihiko .

CANCER, 2009, 115 (15) :3437-3445

[6]

Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies [J].

Al Nakouzi, Nader ;

Le Moulec, Sylvestre ;

Albiges, Laurence ;

Wang, Chris ;

Beuzeboc, Philippe ;

Gross-Goupil, Marine ;

Rouge, Thibault de la Motte ;

Guillot, Aline ;

Gajda, Dorota ;

Massard, Christophe ;

Gleave, Martin ;

Fizazi, Karim ;

Loriot, Yohann .

EUROPEAN UROLOGY, 2015, 68 (02) :228-235

[7]

Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer [J].

Angelergues, Antoine ;

Maillet, Denis ;

Flechon, Aude ;

Ozguroglu, Mustafa ;

Mercier, Florence ;

Guillot, Aline ;

Le Moulec, Sylvestre ;

Gravis, Gwenaelle ;

Beuzeboc, Philippe ;

Massard, Christophe ;

Fizazi, Karim ;

Rouge, Thibault de La Motte ;

Delanoy, Nicolas ;

Elaidi, Reza-Thierry ;

Oudard, Stephane .

EUROPEAN JOURNAL OF CANCER, 2014, 50 (09) :1602-1609

[8]

[Anonymous], J CLIN ONCOL S7

[9]

Biomarkers in the Management and Treatment of Men with Metastatic Castration-Resistant Prostate Cancer [J].

Armstrong, Andrew J. ;

Eisenberger, Mario A. ;

Halabi, Susan ;

Oudard, Stephane ;

Nanus, David M. ;

Petrylak, Daniel P. ;

Sartor, A. Oliver ;

Scher, Howard I. .

EUROPEAN UROLOGY, 2012, 61 (03) :549-559

[10]

Multiparametric MRI for Recurrent Prostate Cancer Post Radical Prostatectomy and Postradiation Therapy [J].

Barchetti, Flavio ;

Panebianco, Valeria .

BIOMED RESEARCH INTERNATIONAL, 2014, 2014

← 1 2 3 4 5 6 7 8 9 10 →